Harry Walker

Noticeable Earnings Watch: Synergy Pharmaceuticals Inc (NASDAQ:SGYP)

Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) jumped 1.10% to reach at $4.61 during the course of session. The company has experienced volume of 4.72M shares while on average the company has a capacity of trading 2.55M shares.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) on August 8, 2016 reported its financial results and business update for the three months ended June 30, 2016.

Second Quarter 2016 and Recent Highlights

Research & Development

Plecanatide CIC Development Update

  • The Food and Drug Administration (FDA) has completed its mid-cycle review meeting of the plecanatide new drug application (NDA) in chronic idiopathic constipation (CIC). To date, no significant issues have been identified. Additionally, the FDA informed us that at this time there are no plans for an advisory committee meeting in connection with its review of the plecanatide NDA in CIC. The plecanatide NDA in CIC is supported by two double-blind placebo-controlled phase 3 trials and one open-label long term safety study. Over 3,500 patients were exposed to plecanatide in the CIC clinical development program. The Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017.
  • In May 2016, we presented additional plecanatide data, including one oral presentation and five posters, at Digestive Disease Week (DDW) 2016. Data presented at DDW showed that plecanatide met the primary and secondary endpoints in two phase 3 CIC clinical trials. In both trials, plecanatide significantly improved durable overall complete spontaneous bowel movement (CSBM) responder rates relative to placebo (primary endpoint). Plecanatide-treated patients also showed immediate and sustained improvements that were statistically significant in CSBM and SBM frequency and stool consistency scores compared to placebo. Furthermore, plecanatide showed statistically significant improvement in abdominal symptoms, such as straining and bloating, as well as constipation severity and treatment satisfaction scores compared to placebo. Most adverse events were mild to moderate in severity; the most common adverse event was diarrhea (<6.0% diarrhea rates in both trials). In addition to the plecanatide CIC clinical data, we presented new in vitro data showing that the pH-dependent activity of plecanatide replicates that of the body’s naturally occurring GI peptide, uroguanylin.

Commercial Planning & Launch Preparation

Our commercial, medical affairs and technical operations teams are continuing to execute on our key strategic imperatives to ensure launch readiness, including the following major initiatives:

Product Readiness

  • Ensuring a robust supply chain process for launch and throughout plecanatide’s life-cycle
  • Building sufficient trade and sample stock for launch in early 2017
  • Implementing our 3PL distribution network
  • Developing and implementing strong Quality Management Systems

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) holds the market capitalization of $895.54M along with 179.78M outstanding shares. The stock traded in the price range of $4.41 – $4.86 for the last trading session. For the stock, price target value has been calculated at $9.90 based on calls of 5 experts. Stock’s minimum price target estimates has been figured out at $4.00 while the maximum price target forecast is established at $15.00.

As of current trade, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has shown weekly upbeat performance of 11.62%. Its six months performance indicated a bullish movement while its yearly performance reflected a negative trend of -42.59%. Year-to-date (YTD) performance of the stock illustrate downbeat trend of -18.69%. Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) currently have an ABR of 1.00, derived from a total of 2 opinions. The company’s price sits 19.02% above from its 50-day moving average of $3.93 and 9.62% above from the stock’s 200-day moving average of $3.52. The company has Relative Strength Index (RSI 14) of 71.54 along with Average True Range (ATR 14) of 0.21. Its weekly and monthly volatility is 6.96%, 5.24% respectively. The company’s beta value is at 1.56.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP)’s price to cash per share for the most recent quarter is 9.59. Synergy Pharmaceuticals Inc (NASDAQ:SGYP)’s quick ratio for most recent quarter is 4.50 along with current ratio for most recent quarter of 4.50. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has a Return on Assets of -117.00%. The company currently has a Return on Equity of 542.10%.

Stock’s Buzz on Earnings: Dean Foods Co (NYSE:DF)

Shares of Dean Foods Co (NYSE:DF) fell -3.48% to reach at $18.16 during the course of session. The company has experienced volume of 5.45M shares while on average the company has a capacity of trading 1.55M shares.

Dean Foods Co (NYSE:DF) on August 8, 2016 reported second quarter 2016 results.

Highlights

  • Q2 net income per diluted share was $0.36 and adjusted net income per diluted share was $0.38, toward the high end of previous provided guidance
  • Q2 operating income of $73 million demonstrates continued year-over-year improvement, driven by diligent cost focus and pricing discipline
  • Acquisition of Friendly’s ice cream business completed June 20
  • Q3 2016 diluted earnings per share are expected to be $0.28 to $0.36; adjusted diluted earnings per share are expected to be $0.32 to $0.40

The second quarter 2016 average Class I Mover, a measure of raw milk costs, was $13.53 per hundred-weight, an approximately 7% sequential decrease from the first quarter 2016 and a decrease of nearly 15% from the second quarter 2015. The third quarter 2016 average Class I Mover forecast of $15.00 per hundred-weight represents an approximately 11% increase sequentially but an approximately 8% decline year-over-year.

Total volume across all products was 632 million gallons for the second quarter 2016, a 3.2% decline compared to total volume of 653 million gallons in the second quarter 2015. For the third quarter 2016, as compared to the prior year period, the Company expects total volumes to decline in the low single digits, but improving versus recent trends.

Based on fluid milk sales data published by the USDA through May, fluid milk volumes improved sequentially from a 0.6% decline in the first quarter of 2016 to a 0.1% increase in the second quarter of 2016 on an unadjusted basis. On this same basis, Dean Foods’ share of U.S. fluid milk volumes decreased by 10 basis points sequentially to 34.5% for the quarter-to-date through May.

Dean Foods Co (NYSE:DF) holds the market capitalization of $1.71B along with 91.77M outstanding shares. The stock traded in the price range of $17.19 – $18.38 for the last trading session. For the stock, price target value has been calculated at $20.80 based on calls of 10 experts. Stock’s minimum price target estimates has been figured out at $17.00 while the maximum price target forecast is established at $23.00.

As of current trade, Dean Foods Co (NYSE:DF) has shown weekly downbeat performance of -3.86%. Its six months performance indicated a bearish movement while its yearly performance reflected a positive trend of 4.23%. Year-to-date (YTD) performance of the stock illustrate upbeat trend of 6.92%. Shares of Dean Foods Co (NYSE:DF) currently have an ABR of 2.04, derived from a total of 7 opinions. The company’s price sits -0.35% below from its 50-day moving average of $18.82 and -0.07% below from the stock’s 200-day moving average of $18.39. The company has Relative Strength Index (RSI 14) of 45.86 along with Average True Range (ATR 14) of 0.55. Its weekly and monthly volatility is 3.45%, 2.57% respectively. The company’s beta value is at 0.36.

Dean Foods Co (NYSE:DF)’s price to sales ratio for trailing twelve months is 0.21 and price to book ratio for most recent quarter is 2.88, whereas price to cash per share for the most recent quarter is 19.91. Dean Foods Co (NYSE:DF)’s price to free cash flow for trailing twelve months is 15.50. Its quick ratio for most recent quarter is 1.20 along with current ratio for most recent quarter of 1.60. Total debt to equity ratio of the company for most recent quarter is 1.44 whereas long term debt to equity ratio for most recent quarter is 1.44. Dean Foods Co (NYSE:DF) has a Return on Assets of 4.20%. The company currently has a Return on Equity of 18.70% and Return on Investment of 4.00%.

Jacobs Engineering Group Inc (NYSE:JEC): What to Expect From Earnings?

Jacobs Engineering Group Inc (NYSE:JEC) plunged -0.69% or -0.37 points during previous trade after opening at the price of $53.92, a total of 1.12M shares exchanged hands compared with its average trading volume of 812,481.00 shares. The stock has a market capitalization of $6.60B and it has 121.93M outstanding shares.

According to consensus agreement of 15 analysts Jacobs Engineering Group Inc (NYSE:JEC) will report earnings per share of $0.75 in their quarterly report and it is expected to announce the company’s results on 8/9/2016 BMO. For the current quarter the company has highest EPS estimates of $0.8 and low forecast is $0.68. However a year ago for the same quarter the company has reported $0.97 earnings per share.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $0.68 while the company reported $0.75 EPS on 5/5/2016 BMO with a difference of 0.07 marking a surprise factor of 10.29%.

Previously for the quarter ended on 12/2015, Jacobs Engineering Group Inc (NYSE:JEC)’s expected mean EPS was $0.69, the company reported its quarterly earnings per share of $0.78 on 2/3/2016 BMO, beating the analysts’ consensus estimate by 0.09 with surprise factor of 13.04%.

Jacobs Engineering Group Inc (NYSE:JEC)’s mean EPS estimate was $0.76 for the quarter ended on 9/2015, while it reported EPS of $0.80 on 11/23/2015 BMO, beating the analysts’ consensus estimate by 0.04 with surprise factor of 5.26%.

Back on 7/28/2015 the company’s estimated EPS value was $0.74 and it reported $0.97 earnings per share (EPS) for the quarter ended on 6/2015. The company posted a positive surprise factor of 31.08% by 0.23.

Average EPS forecast for the current year is $3.07 according to 17 analysts making projections for Jacobs Engineering Group Inc (NYSE:JEC). The most expectant earnings per share estimate of the stock is set at $3.17 while the conservative estimates kept at $2.96 over the current year. Having a look at the historical EPS report, the company attained $3.26 EPS for the previous year. While revenue estimates for the current year is 11.29B, setting the highest revenues estimates of 11.53B and indicating lowest revenues at 10.75B according to agreement of 15 number of analysts. Current revenue movements show that, the company has set average revenue estimates of 2.79B covering forecast of 15 analysts. The company indicates a peak revenue level of 2.89B and 2.63B at bottom level.

Having a glance at growth estimates of the company, it has current quarter growth estimates of -22.70% whereas for next quarter it has 1.30% estimations over growth. Its forecasts over growth are -5.80% during current year while analysts’ growth estimation for the next year is 7.50%. Past 5 years growth of Jacobs Engineering Group Inc (NYSE:JEC) observed at 3.61%, and for the next five years the analysts that follow this company are expecting its growth at 5.75%.

Jacobs Engineering Group Inc (NYSE:JEC) reached at $53.39 price level during last trade its distance from 20 days simple moving average is 0.42%, and its distance from 50 days simple moving average is 3.23% while it has a distance of 20.44% from the 200 days simple moving average. On year trading price range hit the peak level of $54.54 and touched the lowest level of $34.76 and its distance from 52 week high is -2.11% and current price is above +53.60% from 52 week low.

Estimations under Considerations: Tobira Therapeutics Inc (NASDAQ:TBRA)

Tobira Therapeutics Inc (NASDAQ:TBRA) plunged -4.66% or -0.19 points during previous trade after opening at the price of $4.10, a total of 1.42M shares exchanged hands compared with its average trading volume of 374,393.00 shares. The stock has a market capitalization of $42.70M and it has 18.82M outstanding shares.

According to consensus agreement of 4 analysts Tobira Therapeutics Inc (NASDAQ:TBRA) will report earnings per share of $-0.63 in their quarterly report and it is expected to announce the company’s results on 8/9/2016 AMC. For the current quarter the company has highest EPS estimates of $-0.56 and low forecast is $-0.68. However a year ago for the same quarter the company has reported $-1.71 earnings per share.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $-0.53 while the company reported $-0.65 EPS on 5/9/2016 AMC with a difference of -0.12 marking a surprise factor of -22.64%.

Previously for the quarter ended on 12/2015, Tobira Therapeutics Inc (NASDAQ:TBRA)’s expected mean EPS was $-0.52, the company reported its quarterly earnings per share of $-0.5 on 3/3/2016 AMC, beating the analysts’ consensus estimate by 0.02 with surprise factor of 3.85%.

Tobira Therapeutics Inc (NASDAQ:TBRA)’s mean EPS estimate was $-1 for the quarter ended on 9/2015, while it reported EPS of $-0.6 on 11/10/2015 AMC, beating the analysts’ consensus estimate by -0.40 with surprise factor of 40.00%.

Average EPS forecast for the current year is $-2.49 according to 4 analysts making projections for Tobira Therapeutics Inc (NASDAQ:TBRA). The most expectant earnings per share estimate of the stock is set at $-2.34 while the conservative estimates kept at $-2.7 over the current year. Having a look at the historical EPS report, the company attained $-2.66 EPS for the previous year. While revenue estimates for the current year is 400K, setting the highest revenues estimates of 710K and indicating lowest revenues at 100K according to agreement of 2 number of analysts. Current revenue movements show that, the company has set average revenue estimates of 50K covering forecast of 3 analysts. The company indicates a peak revenue level of 150K.

Having a glance at growth estimates of the company, it has current quarter growth estimates of 63.20% whereas for next quarter it has -45.20% estimations over growth. Its forecasts over growth are 6.40% during current year while analysts’ growth estimation for the next year is 5.60%. Past 5 years growth of Tobira Therapeutics Inc (NASDAQ:TBRA) observed at 0.00%, and for the next five years the analysts that follow this company are expecting its growth at -46.16%.

Tobira Therapeutics Inc (NASDAQ:TBRA) reached at $3.89 price level during last trade its distance from 20 days simple moving average is -50.46%, and its distance from 50 days simple moving average is -60.94% while it has a distance of -56.69% from the 200 days simple moving average. On year trading price range hit the peak level of $14.78 and touched the lowest level of $3.76 and its distance from 52 week high is -74.72% and current price is above +3.46% from 52 week low.

Stock Earnings Estimates under Discussion: Myriad Genetics, Inc. (NASDAQ:MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN) plunged -1.54% or -0.47 points during previous trade after opening at the price of $30.50, a total of 1.63M shares exchanged hands compared with its average trading volume of 930,843.00 shares. The stock has a market capitalization of $2.06B and it has 70.30M outstanding shares.

According to consensus agreement of 15 analysts Myriad Genetics, Inc. (NASDAQ:MYGN) will report earnings per share of $0.38 in their quarterly report and it is expected to announce the company’s results on 8/9/2016 BMO. For the current quarter the company has highest EPS estimates of $0.39 and low forecast is $0.36. However a year ago for the same quarter the company has reported $0.41 earnings per share.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $0.38 while the company reported $0.41 EPS on 5/3/2016 BMO with a difference of 0.03 marking a surprise factor of 7.89%.

Previously for the quarter ended on 12/2015, Myriad Genetics, Inc. (NASDAQ:MYGN)’s expected mean EPS was $0.41, the company reported its quarterly earnings per share of $0.45 on 2/2/2016 BMO, beating the analysts’ consensus estimate by 0.04 with surprise factor of 9.76%.

Myriad Genetics, Inc. (NASDAQ:MYGN)’s mean EPS estimate was $0.35 for the quarter ended on 9/2015, while it reported EPS of $0.41 on 11/3/2015 BMO, beating the analysts’ consensus estimate by 0.06 with surprise factor of 17.14%.

Back on 8/11/2015 the company’s estimated EPS value was $0.41 and it reported $0.41 earnings per share (EPS) for the quarter ended on 6/2015.

Average EPS forecast for the current year is $1.65 according to 17 analysts making projections for Myriad Genetics, Inc. (NASDAQ:MYGN). The most expectant earnings per share estimate of the stock is set at $1.66 while the conservative estimates kept at $1.63 over the current year. Having a look at the historical EPS report, the company attained $1.45 EPS for the previous year. While revenue estimates for the current year is 755.46M, setting the highest revenues estimates of 768M and indicating lowest revenues at 751.85M according to agreement of 17 number of analysts. Current revenue movements show that, the company has set average revenue estimates of 187.92M covering forecast of 12 analysts. The company indicates a peak revenue level of 191M and 187M at bottom level.

Having a glance at growth estimates of the company, it has current quarter growth estimates of -7.30% whereas for next quarter it has 4.90% estimations over growth. Its forecasts over growth are 13.80% during current year while analysts’ growth estimation for the next year is 7.90%. Past 5 years growth of Myriad Genetics, Inc. (NASDAQ:MYGN) observed at 6.41%, and for the next five years the analysts that follow this company are expecting its growth at 14.24%.

Myriad Genetics, Inc. (NASDAQ:MYGN) reached at $29.99 price level during last trade its distance from 20 days simple moving average is -5.11%, and its distance from 50 days simple moving average is -5.48% while it has a distance of -19.67% from the 200 days simple moving average. On year trading price range hit the peak level of $46.24 and touched the lowest level of $28.82 and its distance from 52 week high is -35.14% and current price is above +4.06% from 52 week low.

Clean Energy Fuels Corp (NASDAQ:CLNE): What to Expect From Earnings?

Clean Energy Fuels Corp (NASDAQ:CLNE) soared 1.78% or +0.05 points during previous trade after opening at the price of $2.85, a total of 2.05M shares exchanged hands compared with its average trading volume of 1.45M shares. The stock has a market capitalization of $304.69B and it has 105.40M outstanding shares.

According to consensus agreement of 4 analysts Clean Energy Fuels Corp (NASDAQ:CLNE) will report earnings per share of $-0.14 in their quarterly report and it is expected to announce the company’s results on 8/9/2016 AMC. For the current quarter the company has highest EPS estimates of $-0.09 and low forecast is $-0.17. However a year ago for the same quarter the company has reported $-0.29 earnings per share.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $-0.2 while the company reported $0.03 EPS on 5/5/2016 AMC with a difference of 0.23 marking a surprise factor of 115.00%.

Previously for the quarter ended on 12/2015, Clean Energy Fuels Corp (NASDAQ:CLNE)’s expected mean EPS was $-0.1, the company reported its quarterly earnings per share of $0.54 on 3/3/2016 AMC, beating the analysts’ consensus estimate by 0.64 with surprise factor of 640.00%.

Clean Energy Fuels Corp (NASDAQ:CLNE)’s mean EPS estimate was $-0.31 for the quarter ended on 9/2015, while it reported EPS of $-0.26 on 11/5/2015 AMC, beating the analysts’ consensus estimate by 0.05 with surprise factor of 16.13%.

Back on 8/5/2015 the company’s estimated EPS value was $-0.34 and it reported $-0.32 earnings per share (EPS) for the quarter ended on 6/2015. The company posted a positive surprise factor of 5.88% by 0.02.

Average EPS forecast for the current year is $-0.33 according to 4 analysts making projections for Clean Energy Fuels Corp (NASDAQ:CLNE). The most expectant earnings per share estimate of the stock is set at $-0.15 while the conservative estimates kept at $-0.4 over the current year. Having a look at the historical EPS report, the company attained $-0.75 EPS for the previous year. While revenue estimates for the current year is 394.4M, setting the highest revenues estimates of 406M and indicating lowest revenues at 371.6M according to agreement of 3 number of analysts. Current revenue movements show that, the company has set average revenue estimates of 94.33M covering forecast of 3 analysts. The company indicates a peak revenue level of 98M and 88.6M at bottom level.

Having a glance at growth estimates of the company, it has current quarter growth estimates of 51.70% whereas for next quarter it has 52.20% estimations over growth. Its forecasts over growth are 56.00% during current year while analysts’ growth estimation for the next year is -42.40%. Past 5 years growth of Clean Energy Fuels Corp (NASDAQ:CLNE) observed at 0.00%, and for the next five years the analysts that follow this company are expecting its growth at 25.00%.

Clean Energy Fuels Corp (NASDAQ:CLNE) reached at $2.86 price level during last trade its distance from 20 days simple moving average is -9.22%, and its distance from 50 days simple moving average is -13.56% while it has a distance of -16.28% from the 200 days simple moving average. On year trading price range hit the peak level of $6.44 and touched the lowest level of $2.15 and its distance from 52 week high is -55.59% and current price is above +33.02% from 52 week low.

Stock’s Earnings Analysis: Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Ionis Pharmaceuticals Inc (NASDAQ:IONS) plunged -0.58% or -0.21 points during previous trade after opening at the price of $36.31, a total of 2.06M shares exchanged hands compared with its average trading volume of 2.92M shares. The stock has a market capitalization of $4.28B and it has 120.78M outstanding shares.

According to consensus agreement of 12 analysts Ionis Pharmaceuticals Inc (NASDAQ:IONS) will report earnings per share of $-0.53 in their quarterly report and it is expected to announce the company’s results on 8/9/2016 BMO. For the current quarter the company has highest EPS estimates of $-0.39 and low forecast is $-0.75. However a year ago for the same quarter the company has reported $0.29 earnings per share.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $-0.5 while the company reported $-0.52 EPS on 5/4/2016 BMO with a difference of -0.02 marking a surprise factor of 4.00%.

Previously for the quarter ended on 12/2015, Ionis Pharmaceuticals Inc (NASDAQ:IONS)’s expected mean EPS was $-0.47, the company reported its quarterly earnings per share of $-0.59 on 2/25/2016 BMO, missing the analysts’ consensus estimate by -0.12 with surprise factor of 25.53%.

Average EPS forecast for the current year is $-1.5 according to 13 analysts making projections for Ionis Pharmaceuticals Inc (NASDAQ:IONS). The most expectant earnings per share estimate of the stock is set at $-0.73 while the conservative estimates kept at $-2.05 over the current year. Having a look at the historical EPS report, the company attained $-0.74 EPS for the previous year. While revenue estimates for the current year is 279.76M, setting the highest revenues estimates of 329.87M and indicating lowest revenues at 197.5M according to agreement of 13 number of analysts. Current revenue movements show that, the company has set average revenue estimates of 37.69M covering forecast of 12 analysts. The company indicates a peak revenue level of 56M and 25.2M at bottom level.

Having a glance at growth estimates of the company, it has current quarter growth estimates of -282.80% whereas for next quarter it has 110.00% estimations over growth. Its forecasts over growth are -55.40% during current year while analysts’ growth estimation for the next year is 0.90%. Past 5 years growth of Ionis Pharmaceuticals Inc (NASDAQ:IONS) observed at 0.00%, and for the next five years the analysts that follow this company are expecting its growth at 41.00%.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) reached at $35.91 price level during last trade its distance from 20 days simple moving average is 20.81%, and its distance from 50 days simple moving average is 40.14% while it has a distance of 4.82% from the 200 days simple moving average. On year trading price range hit the peak level of $65.34 and touched the lowest level of $19.59 and its distance from 52 week high is -37.50% and current price is above +83.28% from 52 week low.

Technical Analysis on Earnings Estimates: Ocular Therapeutix Inc (NASDAQ:OCUL)

Ocular Therapeutix Inc (NASDAQ:OCUL) plunged -5.56% or -0.36 points during previous trade after opening at the price of $6.62, a total of 2.74M shares exchanged hands compared with its average trading volume of 989,821.00 shares. The stock has a market capitalization of $173.90M and it has 24.77M outstanding shares.

According to consensus agreement of 3 analysts Ocular Therapeutix Inc (NASDAQ:OCUL) will report earnings per share of $-0.49 in their quarterly report and it is expected to announce the company’s results on 8/9/2016 BMO. For the current quarter the company has highest EPS estimates of $-0.46 and low forecast is $-0.51. However a year ago for the same quarter the company has reported $-0.45 earnings per share.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $-0.45 while the company reported $-0.44 EPS on 5/10/2016 BMO with a difference of 0.01 marking a surprise factor of 2.22%.

Previously for the quarter ended on 12/2015, Ocular Therapeutix Inc (NASDAQ:OCUL)’s expected mean EPS was $-046, the company reported its quarterly earnings per share of $-0.43 on 3/10/2016 BMO, beating the analysts’ consensus estimate by 0.03 with surprise factor of 6.52%.

Ocular Therapeutix Inc (NASDAQ:OCUL)’s mean EPS estimate was $-0.33 for the quarter ended on 9/2015, while it reported EPS of $-0.47 on 11/10/2015 AMC, missing the analysts’ consensus estimate by -0.14 with surprise factor of 42.42%.

Back on 8/10/2015 the company reported $-0.45 earnings per share (EPS) for the quarter ended on 6/2015.

Average EPS forecast for the current year is $-1.86 according to 4 analysts making projections for Ocular Therapeutix Inc (NASDAQ:OCUL). The most expectant earnings per share estimate of the stock is set at $-1.75 while the conservative estimates kept at $-1.97 over the current year. Having a look at the historical EPS report, the company attained $-1.71 EPS for the previous year. While revenue estimates for the current year is 3.01M, setting the highest revenues estimates of 5M and indicating lowest revenues at 2.2M according to agreement of 4 number of analysts. Current revenue movements show that, the company has set average revenue estimates of 550K covering forecast of 2 analysts. The company indicates a peak revenue level of 600K and 500K at bottom level.

Having a glance at growth estimates of the company, it has current quarter growth estimates of -8.90% whereas for next quarter it has -4.30% estimations over growth. Its forecasts over growth are -8.80% during current year while analysts’ growth estimation for the next year is -29.60%.

Ocular Therapeutix Inc (NASDAQ:OCUL) reached at $6.11 price level during last trade its distance from 20 days simple moving average is 23.46%, and its distance from 50 days simple moving average is -0.12% while it has a distance of -27.88% from the 200 days simple moving average. On year trading price range hit the peak level of $22.92 and touched the lowest level of $4.04 and its distance from 52 week high is -74.00% and current price is above +51.24% from 52 week low.

Coach Inc (NYSE:COH): Can the Stock Surprise in Next Earnings?

Coach Inc (NYSE:COH) plunged -1.34% or -0.56 points during previous trade after opening at the price of $42.16, a total of 9.34M shares exchanged hands compared with its average trading volume of 3.55M shares. The stock has a market capitalization of $11.70B and it has 278.03M outstanding shares.

According to consensus agreement of 29 analysts Coach Inc (NYSE:COH) will report earnings per share of $0.41 in their quarterly report and it is expected to announce the company’s results on 8/9/2016 BMO. For the current quarter the company has highest EPS estimates of $0.45 and low forecast is $0.38. However a year ago for the same quarter the company has reported $0.31 earnings per share.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $0.41 while the company reported $0.44 EPS on 4/26/2016 BMO with a difference of 0.03 marking a surprise factor of 7.32%.

Previously for the quarter ended on 12/2015, Coach Inc (NYSE:COH)’s expected mean EPS was $0.65, the company reported its quarterly earnings per share of $0.68 on 1/26/2016 BMO, beating the analysts’ consensus estimate by 0.03 with surprise factor of 4.62%.

Coach Inc (NYSE:COH)’s mean EPS estimate was $0.39 for the quarter ended on 9/2015, while it reported EPS of $0.41 on 10/27/2015 BMO, beating the analysts’ consensus estimate by 0.02 with surprise factor of 5.13%.

Back on 8/4/2015 the company’s estimated EPS value was $0.29 and it reported $0.31 earnings per share (EPS) for the quarter ended on 6/2015. The company posted a positive surprise factor of 6.90% by 0.02.

Average EPS forecast for the current year is $1.93 according to 33 analysts making projections for Coach Inc (NYSE:COH). The most expectant earnings per share estimate of the stock is set at $1.98 while the conservative estimates kept at $1.9 over the current year. Having a look at the historical EPS report, the company attained $1.92 EPS for the previous year. While revenue estimates for the current year is 4.5B, setting the highest revenues estimates of 4.55B and indicating lowest revenues at 4.45B according to agreement of 31 number of analysts. Current revenue movements show that, the company has set average revenue estimates of 1.17B covering forecast of 27 analysts. The company indicates a peak revenue level of 1.21B and 1.12B at bottom level.

Having a glance at growth estimates of the company, it has current quarter growth estimates of -32.30% whereas for next quarter it has 17.10% estimations over growth. Its forecasts over growth are 0.50% during current year while analysts’ growth estimation for the next year is 14.00%. Past 5 years growth of Coach Inc (NYSE:COH) observed at -13.00%, and for the next five years the analysts that follow this company are expecting its growth at 8.91%.

Coach Inc (NYSE:COH) reached at $41.45 price level during last trade its distance from 20 days simple moving average is -2.71%, and its distance from 50 days simple moving average is 2.11% while it has a distance of 14.00% from the 200 days simple moving average. On year trading price range hit the peak level of $43.71 and touched the lowest level of $27.22 and its distance from 52 week high is -5.17% and current price is above +56.60% from 52 week low.

Analytical Report on Price Target: Bruker Corporation (NASDAQ:BRKR)

Bruker Corporation (NASDAQ:BRKR) soared 1.84% during previous trade, a total of 1.10M shares exchanged hands compared with its average trading volume of 1.29M shares. The stock has a market capitalization of $3.65B along with 162.55M outstanding shares. On year trading price range hit the peak level of $29.85 and touched the lowest level of $15.78.

Most recently Bruker Corporation (NASDAQ:BRKR)’s price target was revised on 08/05/16 and according to 15 analysts stock’s price will reach at $25.73 during 52 weeks with standard deviation of 2.92. Stock’s minimum price target estimates has been figured out at $19.00 while the maximum price target forecast is established at $30.00, if we look at the price target with an optimistic approach it has upside potential of 35% from its latest closing price of $22.17.

Historically, if we look at price target revisions during last one month, three weeks ago stock’s price target was revised on 07/05/16 by the analysts. The bullish price estimates of the stock is set at $34.00 while the bearish estimates kept at $25.00 over the next one year. Stock’s 52-week target was retained at $28.67, the estimates indicates a standard deviation of 2.87. After that the stock’s target price was revised on 07/20/16, approximately two weeks ago. Bruker Corporation (NASDAQ:BRKR) highest price target was set at $34.00 and lowest target was at $25.00. The company’s one year price target was secure at $28.67 and its standard deviation of 2.87. Moreover one week ago on 07/26/16 the company’s price target was revised at $28.75 with 52 week price target range of $25.00 – $34.00. The estimates signifies a standard deviation of 3.06.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 2.30. ABR value is precisely based on brokerage recommendations, where out of 10 brokerage recommendations 4 rate Bruker Corporation (NASDAQ:BRKR) stock a Strong Buy, 0 rate the stocks of the company a Buy, 5 rate Hold, 1 rate Sell and 0 recommend a Strong Sell. Most recently on 8/3/2016 the stock of Bruker Corporation (NASDAQ:BRKR) downgraded by Wells Fargo from Outperform to Market Perform. However previously on 4/5/2016 it was downgraded by BofA/Merrill from Neutral to Underperform. A research note issued on 4/5/2016 the stock was downgraded by Leerink Partners from Outperform to Mkt Perform.

Bruker Corporation (NASDAQ:BRKR) performance over the past one year advanced 11.07%, during the last six months the stock rose 1.12%. Quarterly performance of the company shows declining momentum of -19.61% while its last one month trend is negative with -5.42%. Stock’s weekly performance expressed down trend of -11.04%.

According to consensus agreement of 17 analysts Bruker Corporation (NASDAQ:BRKR) will report earnings per share of $0.21 in their quarterly report and it is expected to announce the company’s results on 11/2/16. For the current quarter the company has high EPS estimates of $0.23 in contradiction of low EPS estimates of $0.18. However a year ago for the same quarter the company has reported $0.19 EPS.